Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cytomx Therapeutics, Inc. (CTMX)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 65,160,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, which is an activated antibody-drug conjugates directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, which opens a therapeutic window for targeting CD71; Pacmilimab, which is a Probody therapeutic against PD-L1, a clinically and commercially validated cancer target; and BMS-986249 and BMS-986288, which is the Probody versions of ipilimumab.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 81,650 161,597 190,022 293,938
Total Sell Value $219,979 $267,868 $302,806 $477,708
Total People Sold 3 5 6 6
Total Sell Transactions 4 9 14 28
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 314
  Page 1 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Belvin Marcia SVP, Chief Scientific Officer   •       •      –    2025-06-16 4 S $2.69 $37,334 D/D (13,884) 272,252     -
   Ogden Christopher Chief Financial Officer   •       •      –    2025-06-16 4 S $2.69 $28,540 D/D (10,614) 226,271     -
   Mccarthy Sean A. CEO   •       •      –    2025-06-16 4 S $2.69 $149,264 D/D (55,511) 1,089,684     -
   Belvin Marcia SVP, Chief Scientific Officer   •       •      –    2025-06-13 4 OE $0.00 $0 D/D 37,500 286,136     -
   Ogden Christopher Chief Financial Officer   •       •      –    2025-06-13 4 OE $0.00 $0 D/D 37,500 236,885     -
   Ogden Christopher Chief Financial Officer   •       •      –    2025-06-13 4 S $2.95 $4,841 D/D (1,641) 199,385     -
   Mccarthy Sean A. CEO   •       •      –    2025-06-13 4 OE $0.00 $0 D/D 150,000 1,145,195     -
   Chu Yu-Waye Chief Medical Officer   •       •      –    2025-03-18 4 S $0.60 $2,411 D/D (4,025) 135,725     -
   Mccarthy Sean A. CEO   •       •      –    2025-03-18 4 S $0.60 $22,556 D/D (37,656) 995,195     -
   Belvin Marcia SVP, Chief Scientific Officer   •       •      –    2025-03-18 4 S $0.60 $11,688 D/D (19,512) 248,636     -
   Ogden Christopher Chief Financial Officer   •       •      –    2025-03-18 4 S $0.60 $5,122 D/D (8,551) 201,026     -
   Rowland Lloyd A General Counsel   •       •      –    2025-03-18 4 S $0.60 $6,112 D/D (10,203) 120,594     -
   Belvin Marcia SVP, Chief Scientific Officer   •       •      –    2025-02-04 4/A A $0.00 $0 D/D 92,500 268,148     -
   Chu Yu-Waye Chief Medical Officer   •       •      –    2025-02-04 4 A $0.00 $0 D/D 113,500 139,750     -
   Belvin Marcia SVP, Chief Scientific Officer   •       •      –    2025-02-04 4 A $0.00 $0 D/D 87,500 263,148     -
   Ogden Christopher Chief Financial Officer   •       •      –    2025-02-04 4 A $0.00 $0 D/D 101,500 209,577     -
   Mccarthy Sean A. CEO   •       •      –    2025-02-04 4 A $0.00 $0 D/D 375,000 1,032,851     -
   Ogden Christopher Chief Financial Officer   •       •      –    2024-08-20 4 S $1.23 $2,439 D/D (1,984) 108,077     -
   Ogden Christopher Chief Financial Officer   •       •      –    2024-08-20 4 OE $0.00 $0 D/D 6,875 110,061     -
   Mccarthy Sean A. CEO   •       •      –    2024-08-20 4 S $1.23 $17,082 D/D (13,898) 657,851     -
   Mccarthy Sean A. CEO   •       •      –    2024-08-20 4 OE $0.00 $0 D/D 37,500 671,749     -
   Landau Jeffrey B Chief Business Officer   •       •      –    2024-08-20 4 S $1.23 $5,139 D/D (4,181) 119,056     -
   Landau Jeffrey B Chief Business Officer   •       •      –    2024-08-20 4 OE $0.00 $0 D/D 11,250 123,237     -
   Belvin Marcia SVP, Chief Scientific Officer   •       •      –    2024-08-20 4 S $1.23 $5,139 D/D (4,181) 175,648     -
   Belvin Marcia SVP, Chief Scientific Officer   •       •      –    2024-08-20 4 OE $0.00 $0 D/D 11,250 179,829     -
  314 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us